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Ligand-directed signal bias offers opportunities for
sculpting molecular events, with the promise of
better, safer therapeutics. Critical to the exploitation
of signal bias is an understanding of the molecular
events coupling ligand binding to intracellular sig-
naling. Activation of class B G protein-coupled re-
ceptors is driven by interaction of the peptide N ter-
minus with the receptor core. To understand how
this drives signaling, we have used advanced analyt-
ical methods that enable separation of effects on
pathway-specific signaling from those that modify
agonist affinity and mapped the functional conse-
quence of receptor modification onto three-dimen-
sional models of a receptor-ligand complex. This
yields molecular insights into the initiation of recep-
tor activation and the mechanistic basis for biased
agonism. Our data reveal that peptide agonists can
engage different elements of the receptor extracel-
lular face to achieve effector coupling and biased
signaling providing a foundation for rational design
of biased agonists.
INTRODUCTION
G protein-coupled receptors (GPCRs) are critical for the trans-
mission of extracellular signals across the cell membrane to
initiate intracellular responses (Fredriksson et al., 2003) and are
the leading targets of currently marketed therapeutics (Overing-
ton et al., 2006). It is therefore vital to understandmolecular inter-
actions that govern ligand binding and how these interactions
initiate intracellular signaling. Key advances in GPCR structural
biology have greatly enhanced our knowledge of ligand interac-
tion with GPCRs and yielded insight into receptor activation (re-
viewed in Katritch et al., 2013). However, to date, full-length
structures have only been solved for a subset of class A GPCRs,
mostly in complex with small-molecule ligands and in single1632 Cell 165, 1632–1643, June 16, 2016 ª 2016 The Authors. Publis
This is an open access article under the CC BY license (http://creativeinactive conformations. In contrast, there is limited information
addressing the molecular details by which peptide binding at
class B GPCRs couples to effector activation.
Class B peptide hormone receptors are a subfamily of GPCRs
that are major targets for the treatment of chronic disease,
including type 2 diabetes, obesity, and dis-regulated bone
metabolism (Couvineau and Laburthe, 2012). They include re-
ceptors that bind calcitonin, calcitonin gene-related peptide,
vasoactive intestinal polypeptide, pituitary adenylate cyclase-
activating polypeptide, corticotropin releasing factor (CRF),
gastric inhibitory polypeptide, parathyroid hormone, glucagon,
and glucagon-like peptides (GLP-1 and GLP-2). Class B GPCRs
share the basic seven transmembrane (TM) topology common to
all GPCRs but also possess a large N terminus that forms the
major binding site for selective recognition of peptide ligands
(Couvineau and Laburthe, 2012). Despite sequence divergence
in this region between different receptors, this extracellular
domain (ECD) contains key conserved residues, including three
disulphide bonds that aid in stability and confer structural simi-
larities between receptors.
Structural data for class B receptors are limited to partial do-
mains, including several NMR and crystal structures of pep-
tide-bound N-terminal domains (reviewed in Pal et al., 2012)
and, more recently, two inactive structures of the isolated TM
core of the CRF1 receptor (CRF1R) and the glucagon receptor
(GCGR) (Hollenstein et al., 2013; Siu et al., 2013). This structural
data, along with structure-activity studies, support the proposed
two-domain model for peptide binding to class B GPCRs, with
the a-helical C terminus binding to the receptor N-terminal
ECD and the peptide N terminus interacting with the extracellular
face of the TM bundle (this includes the top of the TMs and the
extracellular loops [ECLs]) (Pal et al., 2012). However, there is
very limited information available to define these N-terminal
peptide interactions with the extracellular face of the receptor
core and even less to indicate how this engagement drives re-
ceptor activation. Photoaffinity and mutagenesis data highlight
the significance of the core domain in both peptide binding
and receptor activation, including residues within the three
ECLs and their juxtamembrane regions of class B GPCRs (Bar-
well et al., 2011; Bergwitz et al., 1997). These studies suggesthed by Elsevier Inc.
commons.org/licenses/by/4.0/).
that the extracellular face of the TM bundle forms a significant
site of receptor interaction and/or plays an important role in sta-
bilizing active receptor conformations in the presence of ago-
nists, allowing for activation of intracellular signaling.
The GLP-1R couples to multiple effectors, and in vivo data
support this as important for normal physiology in both
glucose and energy homeostasis (Baggio and Drucker,
2007). The GLP-1R is an important target for treatment of
type 2 diabetes mellitus, and there are multiple endogenous
peptides that activate this receptor. These include four forms
of GLP-1 and the related peptide oxyntomodulin (Baggio and
Drucker, 2007). In addition, there are clinically approved pep-
tides for treatment of type 2 diabetes, including exendin-4 and
metabolically stabilized forms of GLP-1 (Reid, 2013). N-termi-
nally truncated forms of these peptides are antagonists, for
example exendin-4(9-39). In previous studies, we identified
exendin-4 and oxyntomodulin as biased agonists relative to
GLP-1 (GLP-1(7-36)NH2) (Koole et al., 2010; Wootten et al.,
2013a). The phenomenon of biased agonism describes the
ability of different ligands acting at the same receptor to pro-
mote distinct cellular responses (Kenakin and Christopoulos,
2013). Intriguingly, a biased GLP-1R peptide agonist, P5,
that maintains G protein signaling, while exhibiting attenuated
b-arrestin recruitment, induced adiposity and was more effec-
tive at correcting hyperglycaemia in diabetic animals than
exendin-4, despite having markedly lower insulinotropic prop-
erties (Zhang et al., 2015). This highlights the potential utility of
biased agonists as novel GLP-1R therapeutics.
Biased agonism is currently of great interest for drug discov-
ery, with the potential to sculpt cellular responses to favor ther-
apeutically beneficial signaling pathways over those leading to
harmful effects. However, the mechanistic basis underlying
biased signaling needs to be understood if this is to be exploited
for rational drug design. Pleiotropic coupling of the GLP-1R
leads to cAMP production, Ca2+ mobilization, and phosphoryla-
tion of ERK1/2 (pERK1/2) (Koole et al., 2010), each of which are
physiologically important (Baggio and Drucker, 2007). The
contribution of these signaling pathways and the extent to which
one is activated relative to another is therefore important for
optimal development of therapeutics. Existing data demonstrate
that biased signaling does indeed occur at the GLP-1R; how-
ever, the mechanistic basis for this is unknown (Koole et al.,
2010; Wootten et al., 2013a).
Using a combination of alanine-scanning mutagenesis, fol-
lowed by pharmacological quantification of the effects of mu-
tation on peptide agonist affinity and three distinct signaling
pathways, we have identified critical regions within the extra-
cellular face of the receptor core both for peptide agonist af-
finity and for driving receptor coupling to distinct signaling
pathways, extending our initial work on ECL2 (Koole et al.,
2012). We used a GLP-1R model in conjunction with experi-
mental data to generate comparative heatmaps of the contri-
bution of the extracellular surface to agonist affinity and
signaling efficacy. These revealed distinct elements of the
extracellular face of the GLP-1R that are engaged to activate
individual signaling pathways in a ligand-dependent manner.
Collectively, the work allows us to yield novel molecular in-
sights into the initiation of receptor activation and the mecha-nistic basis for biased agonism at this important class B
GPCR. This provides a framework to enable future design of
agonists with tailored signal bias for this receptor.
RESULTS
To understand the functional interface at the GLP-1R extracel-
lular surface, we completed alanine-scanning mutagenesis of
the ECLs and adjacent TM residues, coupled with analysis
of ligand affinity and signaling for three key pathways that
are involved in GLP-1R function and rely on different effector
engagement (Figure S1). We assessed three peptides (GLP-
1, oxyntomodulin, and exendin-4) with highly conserved N-ter-
minal sequences that display biased agonism (Figure S2). This
biased agonism can be observed in both the recombinant
cells used in this mutagenesis study and natively expressing
insulinoma cells that display key features of b islets, where
both exendin-4 and oxyntomodulin were biased away from
GLP-1 in promotion of cellular proliferation and reducing
apoptosis, compared to cAMP signaling (Figure S2). In addi-
tion to measurements of agonist binding affinity, the effects
on signaling efficacy for each of the pathways were quantified
using an operational model of agonism (Black and Leff, 1983).
This enables comparison of effects of mutations across the
different signaling pathways and reveals how individual pep-
tide ligands interact with the receptor surface to elicit
signaling. To understand the importance of residues in ligand
binding and function, we developed a full-length, GLP-1-
bound, GLP-1R model (Active model S1) (Wootten et al.,
2016). Residues located within the ECL/TM boundaries of
the N-terminal ECD are numbered based on their location in
the protein sequence. Residues that are located within the
TM bundle also contain, in superscript, the class B numbering
described in Wootten et al. (2013b).
The predicted ECL1 and adjacent TM boundary comprises
23 residues from L201 to S223, ECL2, 23 residues from G285
to L307 and ECL3, 16 residues from D372 to E387. The results
for the pharmacology of ECL2mutants have been published pre-
viously (Koole et al., 2012) and are discussed here, along with
novel data on ECL1 and ECL3, in context of the 3D surface
map developed for the receptor.
All mutant receptors, with the exception of W306A, were ex-
pressed at the cell surface, and most were expressed at levels
equivalent to wild-type (Table S1) (Koole et al., 2012). Of the
ECL1 and ECL3 mutants, only three exhibited a change in
antagonist binding: H374A, an effect specific to exendin-4
(9–39); K383A, which had global effects on peptide binding;
and F381A, which had selective effects dependent on the
peptide (Table S1). Given that only limited mutations grossly
altered cell-surface expression and antagonist affinity, altered
effects on receptor function (affinity and efficacy) for most
engineered mutations are likely a result of loss of direct inter-
actions with ligands (affinity) or of altering (either directly or
indirectly) interactions between receptor side chains and dis-
ruptions to hydrogen bonding networks that are crucial for
the receptor to explore its conformational landscape, thereby
indicating residues that are important in the mechanism of
signal propagation.Cell 165, 1632–1643, June 16, 2016 1633
Figure 1. Agonist Affinity Profiles of GLP-1R ECL Alanine Mutants Reveal the Importance of Individual Residues for Peptide Affinity
pKi values for each peptide were derived from radioligand inhibition-binding experiments. Bars represent differences in calculated affinity (pKi) values for each
mutant relative to the wild-type receptor for GLP-1 (top), oxyntomodulin (middle), and exendin-4 (bottom). Statistical significance of changes in affinity in
comparison with wild-type was determined by one-way analysis of variance and Dunnett’s post-test, and values are indicated with an asterisk (*p < 0.05). Data
that are statistically significant are colored based on the extent of effect. All values are ± SEM of four to six independent experiments, conducted in duplicate.Involvement of the Extracellular Surface in Agonist
Peptide-Binding Affinity
Effects of mutations on agonist affinity were established by het-
erologous competition with the antagonist radioligand (125I-ex-
endin-4 (9–39)) (Table S1) (Koole et al., 2012). The affinity mea-
sures for each mutant were compared to the wild-type to
determine the relative importance of each individual residue in
peptide agonist affinity (Figure 1). These were mapped onto
the 3Dmodel to provide a comparative heatmap of the contribu-
tion of the extracellular surface to agonist affinity (Figure 2, Active
model S1).
Overall, there was a high degree of overlap in the impact of
alanine mutation on binding of GLP-1, exendin-4, and oxynto-
modulin. In 3D space, there is a continuum of residues from
K288, E292, D293, R299, N300 within the proximal part of
ECL2 that link to TM6/ECL3 membrane-proximal residues
D372, E373 and L379, K383, L384 in ECL3 that are globally
important for binding affinity, along with most residues in the
distal segment of ECL2 (Table S1, Figures 1 and 2, Active model
S1).
In addition, M204 at the TM2/ECL1 boundary lines the pep-
tide-binding groove in our model and is important for the affinity
of all peptides. There is an additional network of residues deeper1634 Cell 165, 1632–1643, June 16, 2016in the protein (C296, W297, R380) that are important for GLP-1
and exendin-4 affinity but have little role in oxyntomodulin bind-
ing (Table S1, Figures 1 and 2, Active model S1). L218 within
ECL1 is also important for the affinity of GLP-1 and exendin-4
but not oxyntomodulin. Additionally, L201 lies deeper in the pep-
tide groove of the protein and is important for GLP-1 and oxynto-
modulin affinity but not exendin-4 (Table S1, Figures 1 and 2,
Active model S1). Only a limited number of residues were selec-
tively important for affinity of individual peptides: W214 (ECL1)
and G377 (ECL3) for GLP-1; K202 (ECL1) and F381 (ECL3) for
oxyntomodulin; and T378 and T386 (both in ECL3) for exendin-4.
Of all the residues important for peptide affinity, most are likely
to have indirect effects on peptide binding. Alterations to agonist
affinity can be achieved by the mutation either altering the
conformation of residues that directly interact with the peptide
within the binding pocket or altering the shape of the binding
pocket such that the peptide cannot bind in the same manner.
The only ECL side chains that our modeling predicted to interact
directly with GLP-1 are L201, W297, R299, N300, and R380 (Fig-
ure S3). This includes three residues that, when mutated, have
differential effects on peptide affinity. Although all are important
for GLP-1 affinity, alanine mutation of L201 had little effect on ex-
endin-4 affinity, andmutation ofW297 and R380 had no effect on
A B C
Figure 2. Heatmap 3D Representation of the GLP-1R Extracellular Face Based on Affinity-Binding Data
Molecular model of the GLP-1R-GLP-1 complex showing the extracellular surface of the TM bundle. Residues that altered affinity of GLP-1 (A), oxyntomodulin
(B), and exendin-4 (C) when mutated are highlighted. Teal indicates residues that were assessed and did not alter affinity; yellow (3- to 5-fold), pale orange (5- to
10-fold), orange (10- to 30-fold), and red (>30-fold) are residues that statistically altered affinity.oxyntomodulin affinity (Figures 1 and 2, Table S1). This is partic-
ularly interesting, as the residues in the GLP-1 peptide that are
predicted to interact with these side chains are absolutely
conserved in the N terminus of the three peptide ligands (Fig-
ure S3). This implies that differential interactions of the C termi-
nus of the peptides with the N-terminal ECD may differentially
orient the N terminus of these peptides in the binding groove
such that they form distinct interactions with the bundle.
Involvement of the Extracellular Surface in Ligand
Efficacy
Agonist potency is a composite of efficacy and affinity and
cannot be used to distinguish pathway-specific effects of muta-
tions. In contrast, in the operational model, the efficacy term ‘‘t’’
relates receptor occupancy to magnitude of response for an in-
dividual pathway and is independent of ligand affinity, although
not receptor expression levels. However, t values can be
normalized to experimentally determined levels of cell-surface
expression to provide a measure of pathway activation (tc) that
is independent of both affinity and cell-surface expression levels
(Kenakin and Christopoulos, 2013). Concentration response
curves for each of the peptides for cAMP formation, pERK1/2,
and Ca2+ mobilization were established for wild-type and each
receptor mutation to determine EC50 and Emax and tc values
for each pathway for all mutants (Tables S2, S3, and S4). As
with affinity, tc estimates for each mutant receptor were
compared to the wild-type to determine the relative importance
of each residue for efficacy in each pathway (Figures 3, 4, and 5).
Theseweremapped onto the 3Dmodel to provide a comparative
heatmap of the contribution of the extracellular surface to effi-
cacy for individual pathways (Figure 6, Active model S1). Overall,
there was a significant correlation between residues identified as
important for peptide affinity, cAMP formation, and Ca2+ mobili-
zation. Generally, there was less correlation between agonist af-finity and pERK1/2 efficacy with a distinct pattern of residues in
3D space being important for transmitting efficacy down this
pathway (Figures 6 and 7).
Involvement of the Extracellular Surface in Peptide-
Mediated cAMP Formation
Consistent with binding studies, there was a high degree of over-
lap in the impact of alanine mutation on cAMP-mediated
signaling by GLP-1, exendin-4, and oxyntomodulin (Figures 3
and 6; Tables S1 and S2). These residues were concentrated
mainly within ECL2 and themore buried,membrane-proximal re-
gions of ECL1 and ECL3 that included residues deep within the
binding groove important for affinity of these peptides (Figures 3
and 6A–6C, Active model S1). However, when mutated, these
residues had a smaller effect on cAMP efficacy than they did
on affinity (Figures 1, 2, 3, and 6A–6C). An additional residue,
Y205, proximal to the binding groove at the TM2/ECL1 boundary
was important for cAMP efficacy by all three peptides. Further-
more, two residues within the peptide binding groove (W297
and R380) that were important for GLP-1 and exendin-4, but
not oxyntomodulin, affinity were required for all three peptides
to activate this signaling pathway. Here the effect of mutation
was larger for oxyntomodulin (no appreciable cAMP response)
(Figures 2, 3, and 6; Table S2) (Koole et al., 2012). GLP-1 and ex-
endin-4 also engage a large proportion of ECL2 and ECL3 with
only minor contributions from ECL1 for transmission of efficacy
to the cAMP pathway (Figures 3, 6A, and 6C). In contrast, a
large proportion of all three loops contributed to cAMP signaling
via the peptide oxyntomodulin, with more involvement of ECL1
but less involvement of ECL2 compared with GLP-1 and ex-
endin-4 (Figures 3 and 6B). The heatmaps indicate that the
lower-affinity ligand oxyntomodulin engages regions (albeit not
necessarily the same residues) in the extracellular surface similar
to those of GLP-1 and exendin-4 upon binding to the receptorCell 165, 1632–1643, June 16, 2016 1635
Figure 3. Peptide-Dependent Effects of ECL Mutations on cAMP Efficacy
Differences in the coupling efficiency (logtc) for cAMP formation of ECL mutations, compared to the wild-type receptor, by GLP-1 (top), oxyntomodulin (middle),
and exendin-4 (bottom). Statistical significance of changes in coupling efficacy was determined by one-way analysis of variance and Dunnett’s post-test, and
values are indicated with an asterisk (*p < 0.05 compared with wild-type). Data that are statistically significant are colored based on the direction and extent of
effect. All values are logtc ± SEM of four to six independent experiments, conducted in duplicate.but requires distinct regions of this surface to promote confor-
mational transitions leading to formation of cAMP (Figures 2
and 6, Active model S1).
Despite the critical importance of ECL2 and the membrane-
proximal region of ECL3 for all three peptides to couple to
cAMP, the relative contribution of each individual residue within
this region varied considerably between oxyntomodulin and the
other two peptides (Figure 7). This included a number of residues
within ECL2 (Y291, E294, T298, S301, and M303) that were
required for GLP-1- and exendin-4-mediated cAMP accumula-
tion but not for oxyntomodulin and two residues, C296 in ECL2
and E387 in ECL3, that had the reverse profile. In addition, there
were a number of residues that had global effects across all three
peptides but with different magnitudes in the extent of effect
(Figures 3, 6, and 7; Table S2). Only a very limited number of res-
idues were selectively important for cAMP efficacy between
GLP-1 and exendin-4. K202 (ECL1) was selective for GLP-1
only, and Q211 (ECL1), D372, and I382 (ECL3) affected both
GLP-1 and oxyntomodulin but not exendin-4. D222 (ECL1) and
L384 (ECL3) were selective for exendin-4 only, whereasmutation
of S223 (ECL1), D293, Y305 (ECL2), and K383 (ECL3) altered
cAMP signaling by both exendin-4 and oxyntomodulin but not
GLP-1 (Figures 3, 6, and 7; Table S2).1636 Cell 165, 1632–1643, June 16, 2016Involvement of the Extracellular Surface in Peptide-
Mediated Intracellular Calcium Mobilization
Due to the low efficacy of oxyntomodulin for promoting Ca2+
mobilization, this pathway was only assessed for GLP-1 and ex-
endin-4 (Figures 4, 6D, and 6E, Activemodel S1). Consistent with
binding and cAMP data, a continuum of residues in 3D space
within ECL2 (K288, E292, D293, C296, W297, R299, N300) link-
ing themembrane-proximal residues in ECL3 (D372, E373, L379,
R380, K383), along with most residues in the distal segment of
ECL2, were required for both ligands to promote Ca2+ mobiliza-
tion. However, mutation of these residues had a larger impact on
exendin-4 than on GLP-1, with more mutant receptors unable to
produce a detectable exendin-4-mediated Ca2+ response (Fig-
ures 4, 6D, and 6E). In addition, residues within the TM2/ECL1
membrane-proximal region (L201, K202, M204, Y205, T207)
were globally important for both peptides. There were also addi-
tional residues within the TM4/ECL2 (I286, V287, Y289, L290,
Y291) and the ECL3/TM7 (L384, T386) membrane-proximal por-
tions of ECL2 and ECL3, respectively, that were important for ex-
endin-4-mediated signaling to this pathway, but with little role for
GLP-1 coupling (Figures 4, 6D, and 6E). These residues extend
within 3D space from the continuum of residues that are globally
important.
Figure 4. Peptide-Dependent Effects of ECL Mutations on Efficacy for Ca2+ Mobilization
Differences in the coupling efficiency (logtc) for Ca
2+ mobilization of ECL mutations, compared to the wild-type receptor, by GLP-1 (top) and exendin-4 (bottom).
Statistical significance of changes in coupling efficacy was determined by one-way analysis of variance and Dunnett’s post-test, and values are indicated with an
asterisk (*p < 0.05 compared with wild-type). Data that are statistically significant are colored based on the extent of effect. All values are logtc ±SEM of four to six
independent experiments, conducted in duplicate.Interestingly, mutation of two residues (D215 in ECL1 and
T378 in ECL3) lying outside of the predicted peptide-binding
groove enhances the ability of GLP-1 to promote Ca2+ mobiliza-
tion, and one of these residues (T378) also had the same effect
for exendin-4 (Figures 4 and 6).
Involvement of the Extracellular Surface in
Peptide-Mediated pERK1/2
Mapping mutational effects for coupling to pERK1/2 onto the 3D
model revealed a strikingly distinct pattern in regions of the GLP-
1R extracellular face that were involved in coupling to this
pathway, in comparison to those important for affinity, cAMP,
and Ca2+ mobilization. Whereas these latter aspects of receptor
function required a large area of the protein’s extracellular sur-
face for transmission of signal, residues important for pERK1/2
were localized mainly to membrane-proximal residues of ECL3
(Figures 5 and 6F–6H, Active model S1) with very little involve-
ment (at least for GLP-1 and exendin-4) of ECL2 (themost critical
domain for all other assessed aspects of receptor function). Only
one residue throughout the entire extracellular surface, Y205 in
ECL1, was globally important for coupling all three peptides to
cAMP, iCa2+, and pERK1/2 (Figures 3, 4, 5, 6, and 7).
Despite all three peptides utilizing ECL3 for coupling receptor
activation to pERK1/2, the importance of individual residues
within this loop varied between the ligands. D372, T378 and
R380, and T386 were globally important for signaling by all three
peptides, but for T378 and R380, the effect of mutation varied.
Interestingly, T378A increased the efficacy for GLP-1 and exen-din-4 but had the opposite effect on oxyntomodulin, reducing its
efficacy. The reverse effect was observed for R380A, where
oxyntomodulin efficacy was increased and GLP-1 and exen-
din-4 efficacies were both impaired (Figures 5, 6F–6H, and 7).
This implies that these residues may be important for conforma-
tional switching of the receptor, altering the ensemble of confor-
mations that allow for coupling to this pathway. In addition,
within this loop, E373 was required for both GLP-1 and exen-
din-4 but played little role in the ability of oxyntomodulin to acti-
vate this pathway. Furthermore, mutation of R376, L379, F381,
and I382 significantly altered signaling by GLP-1, with a similar
trend displayed by exendin-4 but little role in oxyntomodulin-
mediated pERK1/2 (Figure 5).
Although, compared to GLP-1, exendin-4 utilized a larger pro-
portion of the extracellular surface for coupling the GLP-1R to
iCa2+ mobilization, mutational effects on pERK1/2 were even
more confined to ECL3 than those for GLP-1. Intriguingly,
despite requiring a very large portion of ECL2 for intracellular
Ca2+ mobilization, this domain played no role in coupling exen-
din-4 binding to pERK1/2. ECL2 played a limited role for GLP-
1 coupling to this pathway with E292 and N300 being important.
These residues were also important for oxyntomodulin coupling
to pERK1/2 along with D293, N302, and Y305 (Figures 5, 6F, and
6G).
Additional residues selectively important for pERK1/2 by indi-
vidual peptides includedM204 andQ213 (ECL1) for GLP-1; L201
(ECL1) and F385 (ECL3) for oxyntomodulin; andW203 (ECL1) for
exendin-4.Cell 165, 1632–1643, June 16, 2016 1637
Figure 5. Peptide-Dependent Effects of ECL Mutations on pERK1/2 Efficacy
Differences in the coupling efficiency (logtc) to pERK1/2 of ECL mutations, compared to the wild-type receptor, by GLP-1 (top), oxyntomodulin (middle), and
exendin-4 (bottom). Statistical significance of changes in coupling efficacy was determined by one-way analysis of variance and Dunnett’s post-test, and values
are indicated with an asterisk (*p < 0.05 compared with wild-type). Data that are statistically significant are colored based on the direction and extent of effect. All
values are logtc ± SEM of four to six independent experiments, conducted in duplicate.DISCUSSION
Ligands binding to GPCRsmodify the conformational landscape
and thus stabilize a subset of conformational ensembles,
providing the basis for both differential efficacy and biased ago-
nism. There is limited information linking the dynamic events of
receptor activation to engagement of specific effector proteins,
and this is particularly true for class B GPCRs. The current study
explores the molecular determinants for ligand affinity and
engagement of signaling. Specifically, we highlight crucial sur-
face residues within a class B GPCR that link initial peptide
agonist interactions to distinct intracellular signaling pathways
and biased agonism.
Peptide interactions with the extracellular surface and TM do-
mains of class B GPCRs promote conformational transitions
required to allow the binding of signaling effectors at the intracel-
lular surface of these receptors. The ability of receptor mutants
to affect signaling at only a single pathway highlights that
different elements of the extracellular face are required for
coupling to different effectors. In addition, differential effects
on signaling by the three peptide agonists following mutation
of individual residues supports the notion that the extracellular
face of the receptor is important for initiating a switch in the1638 Cell 165, 1632–1643, June 16, 2016conformational landscape that the receptor explores, with
different ligands capable of promoting/stabilizing alternative
subsets of ensembles that lead to biased agonism.
Importance of the ECL Regions of the GLP-1R for
Peptide Binding
Large portions of ECL2, ECL3 and the juxtamembrane positions
of TM2/ECL1, ECL2/TM5 and TM6/ECL3 were important for mo-
lecular recognition of all peptide agonists but not for binding of
the N-terminally truncated antagonist exendin-4(9–39). Despite
the separation in sequence of these residues, they are all located
together in 3D space. In addition, there is a network of residues
provided by all three loops lining the cavity entrance in the TM
bundle, and these residues are important for GLP-1 affinity, ex-
tending the peptide-binding groove from theN-terminal ECD into
the TM domain cavity. These residues include L201, M204 (TM2/
ECL1), E294,W297, T298, R299, N300, Y305 (ECL2), R380, L384
(ECL3) (Figure S4). Interestingly, most of these residues appear
to have indirect effects on agonist affinity as only five of these
residues interact directly with GLP-1 in our model (L201,
W297, R299, N300 and R380) (Figure S3).
The peptide-binding groove in the molecular model extends
from the ECLs down into the TM bundle, forming a deep cavity
A B C
D
F G H
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Figure 6. Heatmap 3D Representation of the GLP-1R Extracellular Face Based on Efficacy Data from Three Different Signaling Assays
Molecular model of the GLP-1R-GLP-1 complex showing the extracellular surface of the TM bundle. All residues assessed in this study are shown in the center
box; the locations of residues in ECL1, ECL2, and ECL3 are highlighted in purple, orange, and blue, respectively. Residues that whenmutated altered efficacy are
highlighted in (A)–(H). (A–C) cAMP efficacy of GLP-1 (A), oxyntomodulin (B), and exendin-4 (C); (D and E) Ca2+ efficacy of GLP-1 (D) and exendin-4 (E); (F–H)
pERK1/2 efficacy of GLP-1 (F), oxyntomodulin (G), and pERK1/2 (H). Teal indicates residues that were assessed and did not alter efficacy; yellow (3- to 5-fold),
pale orange (5- to 10-fold), orange (10- to 30-fold), and red (>30-fold) are residues that statistically altered efficacy. The 3D heatmaps can be found in Activemodel
S1 (Data S1).
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Figure 7. 3D Model Illustrating GLP-1R ECL Loop Residues that Are Globally or Selectively Important for GLP-1, Oxyntomodulin, and
Exendin-4
Based on statistical significance (p < 0.05) of effect whenmutated to alanine, experimentally observed effects on peptide affinity and efficacy can bemapped onto
the molecular model to clearly highlight similarities and differences between the three peptide agonists. Residues highlighted in red reduce function (affinity [A] or
efficacy [B and C]) of all three peptides, those in pink selectively reduce GLP-1 only, those in yellow selectively reduce exendin-4 only, and those in green
selectively reduce oxyntomodulin only. A large number of residues are important for both GLP-1 and exendin but not oxyntomodulin, and these are highlighted in
orange. Other colors represent either enhanced function (GLP-1 only/oxyntomoduin only or GLP-1 and exendin) or existence of opposite effects when mutated
on oxyntomodulin compared to GLP-1 and exendin-4.lined by residues in all TMs except TM4 (Figure S4). In addition to
the identified residues within the ECLs, published information on
the requirement of other residues within this proposed cavity for
GLP-1 affinity support our molecular model wherein GLP-1 en-
ters into this cavity upon binding, with its N terminus residing
deep within the helical bundle in the final ligand-docked model
(Figures S3, S4, S5, and S6, Active model S1). Four of the resi-
dues that reside at the bottom of this pocket (R1902.60,
N2403.43, E3646.53, and Q3947.49) form part of a hydrogen bond
network in the inactive, unliganded receptor and are important
for the binding and function of GLP-1 and exendin-4, though
these residues also have roles in the biased agonism of these
peptides (Wootten et al., 2013b, 2016). K1972.67 sits below
L201 and W297 in 3D space and is important for GLP-1 binding
and activation (Coopman et al., 2010). R3105.40 resides below
N300 and also displays reduced potency in cAMPwhenmutated
to alanine. Our model is also consistent with recent extensive
studies on the GCGR (Siu et al., 2013) and CRF1R (Coin et al.,
2013).
Despite the conservation of N-terminal sequence across all
three peptides, oxyntomodulin appears to engage with the1640 Cell 165, 1632–1643, June 16, 2016GLP-1R in a manner that is significantly different from that of ex-
endin-4 and GLP-1. Although this ligand also requires large por-
tions of ECL2 and, although to a lesser degree, the residues L201
and L384 deep in the extracellular surface of the protein, it does
not require some key residues lining the entry to the cavity,
including C296/W297 in ECL2 and R380 in ECL3, that are crucial
for affinity of the other two peptides. The deeper membrane-
proximal residues of ECL2 and ECL3 are also less important,
and other residues such as L218 in ECL1 play no role in the affin-
ity of oxyntomodulin, and this implies that oxyntomodulin, which
has a lower affinity than GLP-1 and exendin-4, may not bind in
the same manner as the other two peptides. This is supported
by previous data that show only a limited role of residues at
the bottom of the binding cavity (R1902.60, N2403.43, E3646.53,
and Q3947.49) in oxyntomodulin affinity or cAMP formation
(Wootten et al., 2013b, 2016). Indeed, a key predicted interaction
in the GLP-1-GLP-1R model occurs between E9 (position 3) of
the peptide and R1902.60 of the receptor. However, oxyntomo-
dulin contains a Q at this position that would not be expected
to form a salt bridge with R1902.60. Modified GLP-1 and oxynto-
modulin peptides where the residue at position 3 is swapped
converts the behavior of these two peptides such that R1902.60 is
required for cAMP production by the modified oxyntomodulin
but not for the modified GLP-1 (Figure S3). This provides strong
evidence validating the positioning of the N-terminal segment
of GLP-1 in our molecular model, and extended molecular dy-
namics (MD) simulation indicates that this interaction is stable
(Figures S5E–S5H).
Although the extreme N terminus of GLP-1 is predicted to
interact in the deep cavity within the TM bundle, MD simulations
where the peptide N terminus is placed in a superficial position in
a model of the open inactive receptor predict that the peptide
ligand initially makes interactions with the extracellular surface
of the GLP-1R prior to movement of the peptide deeper into
the cavity driven by E9 (Figure S5). In the open conformation,
ECLs 2 and 3 reside further apart in 3D space (Figures S5A–
S5D), suggesting that there is also a reorganization of the
ECLs in response to peptide binding with ECL2 and ECL3 mov-
ing closer together in 3D space in the activated, ligand-occupied
receptor (Figures S5E–S5H). Mapping of mutational data (affinity
and efficacy) onto this surface formed by ECL2 and ECL3 reveals
a continuous surface illustrating that this 3D surface is critical for
stabilization of peptide binding and for activation of downstream
effectors (Figures 6 and 7, Active model S1). Taken together with
the extensive crosslinking/cysteine-trapping studies on other
class B GPCRs (Coin et al., 2013; Dong et al., 2012), this sup-
ports a role for both interactions of peptide ligands with the
extracellular loops and deeper interactions within the TMbundle,
which are both important for peptide binding, leading to propa-
gation of signaling in class B GPCRs.
Importance of the ECL Regions of the GLP-1R for
Efficacy
Overall, there was a very high correlation between residues
important for peptide affinity and those linked to efficacy for
cAMP formation and Ca2+ mobilization (Figures 2, 6, and 7).
This is perhaps not surprising as both cAMP and Ca2+ mobiliza-
tion are predominantly G protein-mediated pathways (Figure S1),
and the ternary complex of the agonist-occupied receptor and
effector (e.g., G protein) provides thermodynamically reciprocal
regulation of agonist binding (De Lean et al., 1980). As such,
the heatmaps of mutant effects on agonist affinity are a compos-
ite of direct effects on binding and those allosterically imposed
via the effects of effector coupling, in particular, G protein
coupling. For GLP-1 and exendin-4, unlike effects on affinity,
almost the entire region of ECL2 is required for transmission of
signal. Moreover, the contribution of individual residues varies
between the different functional measures and the two ligands.
Exendin-4 and GLP-1 display a similar efficacy for coupling to
cAMP; however, exendin-4 is less efficient than GLP-1 at
coupling to Ca2+ mobilization (Figure S2). Interestingly, the
Ca2+ responsemediated by exendin-4 is more sensitive to muta-
tions within ECL2, ECL3, and TM2 membrane-proximal regions
of ECL1 than that mediated by GLP-1, perhaps suggesting
that subtle differences in the interactions formed by these li-
gands account for the small distinctions in signaling bias that
are observed experimentally. These subtle differences in bias
and the effect of mutations may be reflective of the nature of
effector coupling that drives stimulation of individual signalingpathways. This is observed in inhibitor studies where relatively
subtle differences were observed between GLP-1 and exen-
din-4, most notably in the relative contribution of Gbg subunits
to pERK1/2 and iCa2+ signaling (Figure S1).
In addition to distinctions in the pattern of residues required
for oxyntomodulin affinity compared to GLP-1 and exendin-4,
there are also significant differences in the pattern of residues
important for coupling the receptor to cAMP. Like the other
two peptides, oxyntomodulin utilizes ECL2 and membrane-
proximal regions of ECL3 for its function, and there is also ev-
idence for the involvement of deeper residues in ECL2 and
ECL3 that were not required for its affinity. However, in contrast
to GLP-1 and exendin-4, there is a large involvement of resi-
dues in ECL1 and no requirement for residues in the proximal
region of ECL2. Oxyntomodulin displays a very distinct sig-
naling profile to GLP-1 (Figure S2), and collectively, the affinity
and cAMP data support the notion that oxyntomodulin does
not interact in the same manner, requiring a much larger portion
of the extracellular surface to engender conformational transi-
tions linking peptide interactions to signaling inside the cell.
Furthermore, in contrast to GLP-1 and exendin-4, a component
of the oxyntomodulin-mediated cAMP production is dependent
on Gbg subunits, suggesting perhaps that a different subset of
adenylate cyclases are activated to generate this cAMP
response.
In addition to the network of interconnected residues along the
extracellular surface of the receptor, a number ofmore distal res-
idues were also identified to contribute to signaling efficacy.
Studies of the GCGR have suggested that interactions between
the receptor ECD and ECLs can occur and that these can influ-
ence conformational transitions required for signaling (Koth
et al., 2012). It is likely that similar interactions also occur for
the GLP-1R, and these may account for the observed effects
of some residues distal to the interconnected networks.
Extended MD simulation of the full-length receptor is consis-
tent with the potential for such interactions to occur (Movies
S1 and S2).
Interactions Determining Activation of Distinct
Signaling Pathways and Promotion of Biased Signaling
Regardless of the ligand, ECL3 is essential for coupling the pep-
tide-receptor interaction to pERK1/2, whereas ECL2 is critical for
coupling of these interactions to cAMP and Ca2+. Using inhibi-
tors to disrupt various G protein- and b-arrestin-mediated
signaling pathways revealed that whereas cAMP andCa2+mobi-
lization are predominantly driven by G protein-mediated
signaling, pERK1/2 is a composite of both G protein- and b-ar-
restin-driven events, with approximately 30%–60% (depending
on the peptide) of the signal attributed to this latter mechanism
(Figure S1). As the signaling events leading to pERK1/2 are
partially independent of G proteins, this may explain why there
is a very distinct region of the receptor required for signaling to
this pathway in comparison to Ca2+ and cAMP signaling, which
are predominantly G protein mediated.
In addition to heatmapping, the data from this study can also
bemapped ontomodels depicting global importance of residues
across sets of ligands or importance of residues for individual li-
gands. In this way, it is easy to visually observe distinct regions ofCell 165, 1632–1643, June 16, 2016 1641
the receptor that can achieve biased agonism. In Figure 7, which
summarizes the three measures of function with data for all three
peptides, the differential importance of regions in the extracel-
lular face for oxyntomodulin compared to GLP-1 and exendin-
4 can be clearly observed. Oxyntomodulin is a highly biased
ligand compared to GLP-1 (and exendin-4), with bias toward
both pERK1/2 signaling and regulatory protein recruitment
(including b-arrestins) (Figure S2), biases that may be linked
given the greater contribution of b-arrestins to the pERK1/2
response of oxyntomodulin relative to the other two peptides
(Figure S1). Therefore, it is not surprising that quite a different
pattern of residues are required for transmission of signal for
this peptide. Compared to GLP-1, exendin-4 only has very minor
bias in its signaling profile for the pathways assessed in the cur-
rent study, and therefore it is not necessarily surprising that the
residues important at the extracellular face for each of these
peptides to signal to various pathways are similar, even if (as
the heatmapping suggests) the extent to which each of these
residues contributes may be different.
Combining this study with previously published quantitative
information of residues that also contribute to conformational
changes associated with activation provides additional context
to how these surface interactions link with intramembranous net-
works to differentially control signaling (Figure S6). This type of
information allows us to begin to understand how initial peptide
interactions at the extracellular surface engage with distinct net-
works of intramembranous residues to link extracellular binding
to engagement of intracellular effectors.
Mapping mutational effects on efficacy onto molecular
models may also provide a basis for rational design of biased
peptide agonists. If the required cellular efficacy for translation
to therapeutic success is known, then this provides an ability to
design peptides that exploit signaling bias therapeutically. This
hypothesis can be tested to some extent using the metabolite
of GLP-1, GLP-1(9-36)NH2. Whereas this ligand lacks the first
two amino acids of GLP-1, including the N-terminal His7 that
is critical for affinity and activation of cAMP (Adelhorst et al.,
1994), it retains mid-regions of the peptide that, in our molecu-
lar model, interact with ECL3. Although unable to activate the
cAMP pathway, the metabolite can still promote pERK1/2 (Fig-
ure S7). This suggests that peptides that maintain interactions
with ECL3 while altering/removing interactions deeper in the
bundle and perhaps with ECL2 could bias ligands toward
pERK1/2; however, it remains to be seen whether ECL3 is a
common activation domain for this subclass of receptors to
promote coupling to b-arrestin-mediated signaling pathways
such as pERK1/2.
Biased agonism is likely to be a crucial element of the function
of class B GPCRs, as many of them can be activated by multiple
endogenous ligands and their receptors are capable of acti-
vating multiple intracellular signaling pathways. Therefore, un-
derstanding the molecular determinants linking ligand interac-
tions to activation of distinct signaling pathways, in addition to
the physiological benefit of activating individual pathways, could
have significant ramifications for future drug development and
may provide the potential to rationally design future drug thera-
pies, and this is highlighted by the in vivo actions of the biased
GLP-1 agonist, P5 (Zhang et al., 2015).1642 Cell 165, 1632–1643, June 16, 2016EXPERIMENTAL PROCEDURES
Molecular Biology
We used Quikchange (Stratagene) to introduce mutations into the GLP-1R
cloned into the pEF5/Frt/V5-Dest vector.
Cell Culture
Stable FlpIn CHO cell lines were generated using Gateway technology. For all
assays, cells were seeded in 96-well plates at a density of 30,000 cells per well.
Radioligand-Binding Assays
Whole-cell competition radioligand bindingwas performed using 125I-exendin-
4(9–39) as the tracer ligand and competing with increasing concentrations of
unlabeled peptide ligands as described previously (Koole et al., 2010).
Cell-Surface Expression
Cell-surface expression was detected either by using a cell-surface ELISA to
detect a double c-Myc epitope label incorporated with the N-terminal region
of the GLP-1R constructs or by calculation of the Bmax in the radioligand-
binding experiments (Koole et al., 2012; Wootten et al., 2016).
Signaling Assays
For cAMP assays, cells were stimulated for 30min in the presence of the phos-
phodiesterase inhibitor IBMX and then lysed. For pERK1/2, cells were stimu-
lated for 6 min (the peak of the response) before lysis. Detection of cAMP
and pERK1/2 in the lysates was performed using Alphascreen technology as
previously described (Koole et al., 2010). Ca2+mobilization was detected using
a Fluo-4-AM dye immediately after ligand addition with an excitation wave-
length of 485 nM and an emission wavelength of 520 nM with values derived
from the peak response.
Data Analysis
Concentration response data were analyzed using a three-parameter logistic
equation to determine affinity, EC50, and Emax values. Efficacy was calculated
by applying the operational model of agonism:
Y =Bottom+
Em  Bottom
1+ ðð10logKA Þ+ ð10log½AÞÞ=ð10ðlogt + log½AÞÞ
where Bottom represents the y value in the absence of ligand, Em is maximal
system stimulation, KA is the agonist-receptor dissociation constant, [A] is
the ligand concentration, and t is the operational measure of efficacy in the sys-
tem, which incorporates signaling efficacy and receptor density. Derived t
values were corrected to cell-surface expression (tc) measured by ELISA,
and errors were propagated from both t and cell-surface expression.
Molecular Modeling
Energy-based conformational modeling of the GLP-1R complex with GLP-1
was performed with Modeler 9.15, and peptide docking and energy optimiza-
tion were guided by published experimental data (Tables S5 and S6), as pre-
viously described (Wootten et al., 2016).
Detailed procedures and analysis are reported in the Supplemental Experi-
mental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, six tables, one data file, and two movies and can be found
with this article online at http://dx.doi.org/10.1016/j.cell.2016.05.023.
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